insights_auto
Outlook: 83.3% bullish·2.4% bearish
Go to analysischevron_right
TLX:ASX
Telix Pharmaceuticals Ltd
A$15.65
arrow_downward
-0.45%(-0.070) 1D
Oct 1, 3:35:35 PM GMT+10 · AUD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TLX...
Open
A$15.69
High
A$15.86
Low
A$15.35
Mkt. cap
5.32B
Avg. vol.
2.41M
Volume
1.30M
P/E ratio
111.21
52-wk high
A$18.22
52-wk low
A$8.26
EPS
A$0.14
Shares outstanding
339.89M
No. of employees
1K
Open
A$15.69
High
A$15.86
Low
A$15.35
Mkt. cap
5.32B
Avg. vol.
2.41M
Volume
1.30M
P/E ratio
111.21
52-wk high
A$18.22
52-wk low
A$8.26
EPS
A$0.14
Shares outstanding
339.89M
No. of employees
1K
News stories
From web sources and news partners
Kalkine Media
·
3 hours ago
Are Telix (ASX:TLX) shares still weighing the ITM merger?
Investing.com
·
17 hours ago
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA designation
TipRanks
·
1 day ago
Telix Wins FDA Fast Track for Pre-Biopsy Prostate Cancer Imaging Program
The Motley Fool Australia
·
1 day ago
Buy, hold, sell: Telix Pharmaceuticals, Qualitas, Greatland Resources shares
About Telix Pharmaceuticals Ltd
CEOChristian Behrenbruch
Employees1.15K
Founded2015
Headquarters-
SectorBiotechnology
Websitetelixpharma.com
Last report
Jul 21, 2026
Fiscal period
Q2 2026
EPS / Est. (AUD)
- / A$0.03
Revenue / Est. (AUD)
347.45M / 341.96M
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 206.72M | 206.72M | 238.68M | 238.68M |
Cost of goods sold | 110.68M | 110.68M | 122.86M | 122.86M |
Cost of revenue | 110.68M | 110.68M | 122.86M | 122.86M |
Research and development expenses | 44.83M | 44.83M | 61.91M | 61.91M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 47.93M | 47.93M | 53.51M | 53.51M |
Operating expense | 92.02M | 92.02M | 92.64M | 92.64M |
Total operating expenses | 202.70M | 202.70M | 215.49M | 215.49M |
Operating income | 4.02M | 4.02M | 23.18M | 23.18M |
Other non operating income | -7.23M | -7.23M | -7.45M | -7.45M |
EBT including unusual items | -215.00K | -215.00K | 14.62M | 14.62M |
EBT excluding unusual items | -6.75M | -6.75M | 13.16M | 13.16M |
Income tax expense | 2.20M | 2.20M | -4.54M | -4.54M |
Effective tax rate | -1,023.95% | -1,023.95% | -31.05% | -31.05% |
Other operating expenses | -745.50K | -745.50K | -22.79M | -22.79M |
Net income | -2.42M | -2.42M | 19.16M | 19.16M |
Net profit margin | -1.17% | -1.17% | 8.03% | 8.03% |
Earnings per share | - | - | - | - |
Interest and investment income | 1.10M | 1.10M | 1.14M | 1.14M |
Interest expense | -3.78M | -3.78M | -3.71M | -3.71M |
Net interest expenses | -2.68M | -2.68M | -2.57M | -2.57M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 7.09M | 7.09M | 28.66M | 28.66M |
Gain or loss from assets sale | - | - | - | - |